PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL FOR ACETONE

被引:33
|
作者
KUMAGAI, S
MATSUNAGA, I
机构
[1] Department of Occupational Health, Osaka Prefectural Inst Public Health, Higashinari-ku, Osaka 537
关键词
ACETONE; PHARMACOKINETIC MODEL; ABSORPTION;
D O I
10.1136/oem.52.5.344
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective-This study aimed to develop a physiologically based pharmacokinetic model for acetone and to predict the kinetic behaviour of acetone in the human body with that model. Methods-The model consists of eight tissue groups in which acetone can be distributed: the mucous layer of the inhaled air tract, the mucous layer of the exhaled air tract, a compartment for gas exchange (alveolus of the lung), a group of blood vessel rich tissues including the brain and heart, a group of tissues including muscles and skin that have low perfusion rates, a group of fatty tissues, an organ for metabolism (liver), and a compartment for urinary excretion (kidney). A mucous layer in the model is only the outermost layer of the mucus lining the wall of the air tract during inhalation and exhalation. To check the relevance of the model, the simulated results were compared with the experimental data. Next, simulation was conducted by changing the volume of the mucous layer and the respiratory rate to clarify the effect of these variables. Finally, simulation of an occupational situation was performed. Results-With an appropriate value for the volume of mucous layer, the simulated acetone concentrations in arterial blood, end exhaled air, urine, and fatty tissue were found to agree well with the experimental data. The volume of mucous layer and rate of respiration were critical for the appropriate simulation. The simulated occupational situation fitted the observed regression line in field studies quite well. The simulation also enabled predictions to be made about the characteristic kinetics for water soluble solvents. Conclusion The model is useful for understanding and explaining the kinetics of acetone.
引用
收藏
页码:344 / 352
页数:9
相关论文
共 50 条
  • [31] Have physiologically-based pharmacokinetic models delivered?
    Edginton, Andrea N.
    Joshi, Ghanashyam
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (08) : 929 - 934
  • [32] Applications of minimal physiologically-based pharmacokinetic models
    Yanguang Cao
    William J. Jusko
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 711 - 723
  • [33] Examination of Physiologically-Based Pharmacokinetic Models of Rosuvastatin
    Bowman, Christine M.
    Ma, Fang
    Mao, Jialin
    Chen, Yuan
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (01): : 5 - 17
  • [34] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING AND BIOACTIVATION OF XENOBIOTICS
    CLEWELL, HJ
    ANDERSEN, ME
    TOXICOLOGY AND INDUSTRIAL HEALTH, 1994, 10 (1-2) : 1 - 24
  • [35] Physiologically-based pharmacokinetic modeling of pyrene in the rat
    Haddad, S
    Withey, J
    Laparé, S
    Law, F
    Krishnan, K
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 1998, 5 (04) : 245 - 255
  • [36] A Δ9-Tetrahydrocannabinol Physiologically-Based Pharmacokinetic Model Development in Humans
    Methaneethorn, Janthima
    Poomsaidorn, Chomkanang
    Naosang, Kanyamas
    Kaewworasut, Parichart
    Lohitnavy, Manupat
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45 (04) : 495 - 511
  • [37] Evaluating a physiologically-based pharmacokinetic model for use in risk assessment.
    Clark, LH
    Barton, HA
    Setzer, RW
    TOXICOLOGICAL SCIENCES, 2003, 72 : 182 - 182
  • [38] Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans
    Jagdale, Prabhas
    Sepp, Armin
    Shah, Dhaval K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2022, 49 (06) : 607 - 624
  • [39] Physiologically-based pharmacokinetic model for pregnancy as a tool for investigation of developmental mechanisms
    Young, JF
    COMPUTERS IN BIOLOGY AND MEDICINE, 1998, 28 (04) : 359 - 364
  • [40] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL TO SUPPORT OPHTHALMIC SUSPENSIONS DEVELOPMENT.
    Le Merdy, M.
    Fan, J.
    Babiskin, A. H.
    Zhao, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S7 - S7